AAPGV - מקדם החזר מותאם קצב צמיחה Ascentage

Ascentage Pharma Group is developing therapies to combat resistant tumors, leveraging patent protection and approvals in China and the US. The issuer is implementing ESG principles by reducing harmful emissions during drug development. Growth in leukemia inhibitor sales and a global pipeline are driving capitalization. The PEG ratio demonstrates fundamental value, where the 0.00 level represents the current figure.

Ascentage Pharma Group (AAPGV) development of innovative BCL-2 inhibitors to combat leukemia resistance requires colossal investments, making the assessment of growth efficiency critically important. By analyzing the PEG ratio, an investor determines whether the share price is justified by earnings dynamics; a value below one signals a fundamental undervaluation of the asset relative to its expansion, serving as a signal to seek high-yield "rockets."